Neuregen
Latest round
- Series A
Last raised
- May 2026
Total raised
- $15M
Investors
- 3
About Neuregen
, dba Neuregen, is a company that develops gene therapy drugs, focusing on drug development using cell transdifferentiation technology and genetic replacement technology with its own intellectual property rights. The company's core team members have experience in in-situ transdifferentiation technology and gene therapy research and come from the Chinese Academy of Sciences, Peking Union Medical College and other institutions. In 2023, the company was honored with awards such as China's Front-Runners (Front-Runners) Top 100 in biopharmaceuticals. The company has established a gene therapy drug R&D platform based on in-situ cellular transdifferentiation technology with independent intellectual property rights, including screening of transdifferentiation factors, design of viral and non-viral vectors, and development of in-vivo and ex-vivo pharmacodynamic methods. Its current product pipeline focuses on neurological diseases, with an emphasis on blinding eye diseases and difficult-to-treat neurological tumors, and extends to major neurodegenerative diseases. The company generates revenue from developing novel gene therapy drugs.
Who invested in Neuregen
3 investors across 2 rounds
See all investors in Neuregen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Neuregen
Who invested in Neuregen?
Neuregen has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Neuregen raised?
Neuregen has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Neuregen last raise money?
Neuregen's most recent round on record is a Series A, in May 2026.
What does Neuregen do?
, dba Neuregen, is a company that develops gene therapy drugs, focusing on drug development using cell transdifferentiation technology and genetic replacement technology with its own intellectual property rights.
Where is Neuregen headquartered?
Neuregen is headquartered in Suzhou, China.
Which VCs invest in companies like Neuregen?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, Taibao Capital and Hengxu Capital back healthcare companies at Neuregen's stage. Their profiles are linked below.
VCs backing healthcare startups at Series A
Raising like Neuregen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.